This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Off-market insider buying at Kane Biotech (KNE)
Philip Renaud, a Director, acquired 20,000,000 Common Shares on a direct ownership basis at a price of $0.050 through a private transaction on May 25th, 2026. The insider also acquired 20,000,000 Warrants on a direct ownership basis with an exercise price of $0.060 for 18 months. This represents a $1,000,000 investment into the company's shares and an account share holdings change of 48.4%.
Let the insiders guide you to opportunity at Canadianinsider.com.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
